VERTEX PHARMACEUTICALS (EUROPE) LIMITED

PaymentCheck Score 2025
56Fair
1.5vs last year
#3287 in UK
#35 in Life Sciences And Medical Technology
#1259 in London

Company Information

Company Number
02907620
Registered Address
2 Kingdom Street, London, England, W2 6BD
Status
Active
Employee Count
564
Turnover
£6,947,775,000
EBITDA
£1,013,082,000

Additional Details

Company Type
Private limited Company
Incorporated On
11 March 1994
Nature of Business
72190 - Other research and experimental development on natural sciences and engineering
Industries
Life Sciences And Medical Technology
Region
London

Time to Pay

Average Time to Pay
41 days
Shortest Period:45 days
Longest Period:90 days
Max Contractual:90 days

Payment Timeline

Within 30 Days
18%
31-60 Days
79%
After 60 Days
3%
Not Paid Within Terms3%

Payment Features

Participates in Codes✗ No
E-Invoicing✗ No
Supply Chain Finance✗ No

Payment Score History

Excellent (80+) Good (60-79) Fair (40-59) Poor (20-39) Very Poor (<20)

Performance Reports History

Reporting Period Filed: 2025-07-25
Reporting PeriodFiling DateAverage Time to Pay (days)Paid within 30 daysPaid 31-60 daysPaid after 60 daysNot Paid within Terms
01 Jan 2025 - 30 Jun 202525 Jul 20254118%79%3%3%
01 Jul 2024 - 31 Dec 202421 Jan 20254021%77%2%4%
01 Jan 2023 - 30 Jun 202326 Jul 20234317%76%7%5%
01 Jan 2022 - 30 Jun 202225 Jul 20224331%68%1%6%
01 Jul 2021 - 31 Dec 202125 Jan 20223435%64%1%3%
01 Jan 2021 - 30 Jun 202114 Jul 20213246%53%1%3%
01 Jul 2020 - 31 Dec 202019 Jan 20213237%62%1%3%

Payment Time Trends

Payment Distribution Trends

Invoice Payment Practices

This information is as reported by the business, and responses are in their own words.

Payment Terms

Standard payment terms

There are some changes to the standard payment terms where suppliers have reduced payment terms for expedited payments agreed with suppliers at the time of contract.

Were there any changes to the standard payment terms in the reporting period?

No information available

Any other information about payment terms

N/A

Maximum contractual payment period agreed

90

Dispute Resolution Process

We operate a purchase order system which reduces the number of fee disputes. Any fee disputes are discussed between relevant supplier and the business owner drawing in legal and sourcing support as needed.

Other Payment Information

Has this business signed up to a code of conduct or standards on payment practices?

For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.

Does this business offer e-invoicing in relation to qualifying contracts?

This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.

Does this business offer supply chain finance?

This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.

Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?

During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?

No information available

Company Summary

VERTEX PHARMACEUTICALS (EUROPE) LIMITED is a pharmaceutical company that operates in Europe. They are committed to sustainability and have implemented various initiatives to reduce their environmental impact.

One of their key sustainability programs is their Green Teams, which are made up of employees who work to identify and implement eco-friendly practices within the company. They also have an active recycling program and have reduced their carbon footprint by using renewable energy sources.

In terms of products and services, VERTEX PHARMACEUTICALS (EUROPE) LIMITED focuses on developing innovative treatments for serious and life-threatening diseases. They have a strong pipeline of drugs in development for conditions such as cystic fibrosis, sickle cell disease, and alpha-1 antitrypsin deficiency.

The company is led by a team of experienced professionals, including their President and CEO, Dr. Reshma Kewalramani. They also have a dedicated team of scientists and researchers who are constantly working towards developing new treatments.

Contact information for VERTEX PHARMACEUTICALS (EUROPE) LIMITED can be found on their website, including their registered office address in London. Their website also provides information on their products, clinical trials, and sustainability efforts.

In summary, VERTEX PHARMACEUTICALS (EUROPE) LIMITED is a leading pharmaceutical company in Europe, with a strong focus on sustainability and developing groundbreaking treatments for serious diseases. Their commitment to sustainability and dedicated team make them a reputable and responsible company in the pharmaceutical industry.

Financial Metrics

Cash
£405,757,257
Net Worth
£1,444,341,392
Total Current Assets
£2,400,013,746
Total Current Liabilities
£1,359,446,106

Company Location